14788

    532872

    SPARC

    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    SUN PHARMA ADV.RES.CO.LTD Share Price Today

    SUN PHARMA ADV.RES.CO.LTD is currently trading at ₹213.21, down by ₹3.76 from the previous close. The stock touched an intraday high of ₹217.03 and a low of ₹211.00 during the latest trading session. Over the past one year, SUN PHARMA ADV.RES.CO.LTD has delivered a return of 54.43%, while the stock has declined 17.09% in the last one month.

    SUN PHARMA ADV.RES.CO.LTD performance

    Today’s low Today’s high
    ₹ 211.00 ₹ 217.03
    ₹ 213.21
    52 week low 52 week high
    ₹ 108.00 ₹ 289.00
    ₹ 213.21
    Open Price ₹ 216.99
    Prev. Close ₹ 216.98
    Volume (Shares) 607331.00
    Total traded value ₹ 1294.89
    Upper Circuit ₹ 238.67
    Lower Circuit ₹ 195.29
    info

    Investment Returns

    Over 1 Month -17.09% Over 3 Months 38.13% Over 6 Months 55.92% Over 1 Year 54.43%
    Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    SUN PHARMA ADV.RES.CO.LTD fundamentals


    • Market cap (Cr) 6,919.10
    • P/E Ratio (TTM) 4.54
    • Beta 1.72
    • Book Value / share 41.09
    • Return on equity 164.77%
    • EPS (TTM) 48.21
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 1,760.70
    info icon alternate text
    • Market cap (Cr) 6,847.40
    • P/E Ratio (TTM) 4.54
    • Beta 1.65
    • Book Value / share 41.09
    • Return on equity 164.77%
    • EPS (TTM) 48.21
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 1,760.70
    info icon alternate text

    SUN PHARMA ADV.RES.CO.LTD Financials

    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 13.20
    Operating Expense 94.32
    Net Profit 1760.70
    Net Profit Margin (%) 13338.63
    Earnings Per Share (EPS) 54.26
    EBITDA 1774.74
    Effective Tax Rate (%) 0.00
    Particulars DEC 2025 (Values in Cr)
    Revenue 8.45
    Operating Expense 76.66
    Net Profit -80.57
    Net Profit Margin (%) -953.49
    Earnings Per Share (EPS) -2.48
    EBITDA -69.22
    Effective Tax Rate (%) 0.00
    Particulars SEP 2025 (Values in Cr)
    Revenue 7.86
    Operating Expense 83.83
    Net Profit -75.97
    Net Profit Margin (%) -966.53
    Earnings Per Share (EPS) -2.34
    EBITDA -65.88
    Effective Tax Rate (%) 0.00
    Particulars JUN 2025 (Values in Cr)
    Revenue 9.64
    Operating Expense 70.69
    Net Profit -52.03
    Net Profit Margin (%) -539.73
    Earnings Per Share (EPS) -1.60
    EBITDA -43.31
    Effective Tax Rate (%) 0.00
    Particulars MAR 2025 (Values in Cr)
    Revenue 27.19
    Operating Expense 88.17
    Net Profit -60.98
    Net Profit Margin (%) -224.27
    Earnings Per Share (EPS) -1.88
    EBITDA -53.92
    Effective Tax Rate (%) 0.00
    Particulars MAR 2026 (Values in Cr)
    Revenue 39.15
    Operating Expense 325.51
    Net Profit 1552.13
    Net Profit Margin (%) 3964.57
    Earnings Per Share (EPS) 47.83
    EBITDA 1596.32
    Effective Tax Rate (%) 0.00
    Particulars MAR 2025 (Values in Cr)
    Revenue 71.77
    Operating Expense 418.78
    Net Profit -345.22
    Net Profit Margin (%) -481.00
    Earnings Per Share (EPS) -10.64
    EBITDA -325.48
    Effective Tax Rate (%) 0.00
    Particulars MAR 2024 (Values in Cr)
    Revenue 75.55
    Operating Expense 493.13
    Net Profit -388.11
    Net Profit Margin (%) -513.71
    Earnings Per Share (EPS) -11.96
    EBITDA -374.32
    Effective Tax Rate (%) 0.00
    Particulars MAR 2023 (Values in Cr)
    Revenue 238.78
    Operating Expense 472.24
    Net Profit -222.58
    Net Profit Margin (%) -93.21
    Earnings Per Share (EPS) -7.82
    EBITDA -203.18
    Effective Tax Rate (%) 0.00
    Particulars MAR 2022 (Values in Cr)
    Revenue 137.25
    Operating Expense 347.49
    Net Profit -203.40
    Net Profit Margin (%) -148.19
    Earnings Per Share (EPS) -7.73
    EBITDA -179.91
    Effective Tax Rate (%) 0.00
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 41.25
    ROE % 164.52
    ROCE % 110.83
    Total Debt to Total Equity 0.74
    EBITDA Margin 85.00
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share -6.68
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin -447.75
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 3.88
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.12
    EBITDA Margin -493.22
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 15.80
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.03
    EBITDA Margin -85.09
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 41.09
    ROE % 164.77
    ROCE % 111.09
    Total Debt to Total Equity 0.74
    EBITDA Margin 84.95
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share -6.80
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin -453.50
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 3.85
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.11
    EBITDA Margin -495.46
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 15.80
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.17
    EBITDA Margin -85.09
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share -7.47
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin -131.07
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 1.15
    Total Assets 2170.87
    Total Liabilities 2170.87
    Total Equity 1338.82
    Share Outstanding 32
    Price to Book Ratio 2.79
    Return on Assets (%) 71.54
    Return on Capital (%) 81.96
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 1.96
    Total Assets 335.53
    Total Liabilities 335.53
    Total Equity -216.94
    Share Outstanding 32
    Price to Book Ratio -21.76
    Return on Assets (%) -102.07
    Return on Capital (%) -830.58
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 155.32
    Total Assets 515.04
    Total Liabilities 515.04
    Total Equity 125.75
    Share Outstanding 32
    Price to Book Ratio 96.09
    Return on Assets (%) -75.18
    Return on Capital (%) -224.14
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 111.57
    Total Assets 830.12
    Total Liabilities 830.12
    Total Equity 512.77
    Share Outstanding 32
    Price to Book Ratio 11.36
    Return on Assets (%) -26.81
    Return on Capital (%) -43.4
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 0.31
    Total Assets 2167.99
    Total Liabilities 2167.99
    Total Equity 1333.58
    Share Outstanding 32
    Price to Book Ratio 2.79
    Return on Assets (%) 71.59
    Return on Capital (%) 82.14
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 1.18
    Total Assets 329.27
    Total Liabilities 329.27
    Total Equity -220.62
    Share Outstanding 32
    Price to Book Ratio -21.76
    Return on Assets (%) -104.84
    Return on Capital (%) -919
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 155.06
    Total Assets 486.33
    Total Liabilities 486.33
    Total Equity 124.85
    Share Outstanding 32
    Price to Book Ratio 96.09
    Return on Assets (%) -79.80
    Return on Capital (%) -225.83
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 111.57
    Total Assets 830.12
    Total Liabilities 830.12
    Total Equity 512.77
    Share Outstanding 32
    Price to Book Ratio 11.36
    Return on Assets (%) -26.81
    Return on Capital (%) -43.4
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 1.22
    Total Assets 280.08
    Total Liabilities 280.08
    Total Equity 31.22
    Share Outstanding 27
    Price to Book Ratio -39.74
    Return on Assets (%) -72.61
    Return on Capital (%) -191.47
    Particulars MAR 2026 (Values in Cr)
    Net Income 1553.00
    Cash from Operations -270.41
    Cash from Investing -23.49
    Cash from Financing 261.38
    Net change in Cash -0.88
    Free Cash Flow -246.58
    Particulars MAR 2025 (Values in Cr)
    Net Income -342.78
    Cash from Operations -369.11
    Cash from Investing 157.66
    Cash from Financing 199.25
    Net change in Cash -3.37
    Free Cash Flow -358.78
    Particulars MAR 2024 (Values in Cr)
    Net Income -386.83
    Cash from Operations -425.07
    Cash from Investing 391.52
    Cash from Financing 42.40
    Net change in Cash 4.74
    Free Cash Flow -398.56
    Particulars MAR 2023 (Values in Cr)
    Net Income -222.58
    Cash from Operations -74.48
    Cash from Investing -548.27
    Cash from Financing 616.75
    Net change in Cash -0.64
    Free Cash Flow -59.09
    Particulars MAR 2026 (Values in Cr)
    Net Income 1552.13
    Cash from Operations -270.52
    Cash from Investing -23.50
    Cash from Financing 261.52
    Net change in Cash -0.87
    Free Cash Flow -246.69
    Particulars MAR 2025 (Values in Cr)
    Net Income -345.22
    Cash from Operations -373.20
    Cash from Investing 157.66
    Cash from Financing 200.87
    Net change in Cash -3.87
    Free Cash Flow -362.86
    Particulars MAR 2024 (Values in Cr)
    Net Income -388.10
    Cash from Operations -425.31
    Cash from Investing 391.11
    Cash from Financing 42.79
    Net change in Cash 4.47
    Free Cash Flow -398.80
    Particulars MAR 2023 (Values in Cr)
    Net Income -222.58
    Cash from Operations -74.48
    Cash from Investing -548.27
    Cash from Financing 616.75
    Net change in Cash -0.64
    Free Cash Flow -59.09
    Particulars MAR 2022 (Values in Cr)
    Net Income -203.39
    Cash from Operations -212.77
    Cash from Investing -29.16
    Cash from Financing 229.32
    Net change in Cash -8.07
    Free Cash Flow -180.09
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 43.93 18.23 2.12 336.65 23.12 45.50
    BLISS GVS PHARMA LTD 493.60 39.74 4.39 5244.20 118.35 552.90
    CIPLA LTD 1475.00 33.30 3.46 119157.18 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 551.60 25.80 3.99 1623.41 256.40 564.50
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 43.93 30.72 5.65 336.65 23.12 45.50
    AMRUTANJAN HEALTH CARE LTD. 519.90 23.30 4.05 1503.06 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8091.35 105.74 23.17 20228.38 7630.00 9850.00
    BLISS GVS PHARMA LTD 493.60 53.42 4.53 5244.20 118.35 552.90

    SUN PHARMA ADV.RES.CO.LTD shareholding pattern

    Holding
    30.33%
    65.67%
    3.9%
    0.09%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    SUN PHARMA ADV.RES.CO.LTD Technicals Summary

    213.21 -1.73 redarrow
    red-green-graph indicator
    9 Bearish
    7 Bullish
    • 5 Days 213.70
    • 26 Days 222.50
    • 10 Days 215.10
    • 50 Days 217.50
    • 12 Days 216.50
    • 100 Days 198.20
    • 20 Days 221.10
    • 200 Days 178.50
    218.59 PIVOT
    First Support 214.37 First Resistance 221.19 Second Support 211.77 Second Resistance 225.41 Third Support 207.55 Third Resistance 228.01
    RSI 45.61 ADX 8.60 MACD -6.01 Williams % R -64.12 Commodity Channel Index (CCI) -33.01
    Date 2026-08-06 Week 509952.00 Same Day 535937.00 Month 785082.00
    1 Year 1.73 3 Year 1.31
    Over 1 Month
    -17.09% down
    Over 1 Year
    54.43% down
    Over 3 Months
    38.13% down
    Over 3 Years
    -2.52% down
    Over 6 Months
    55.92% down
    Over 5 Years
    -5.32% down

    SUN PHARMA ADV.RES.CO.LTD Corporate Actions

    Top Gainers

    Top Losers

    About the Company

    Sun Pharmaceutical Industries Limited was founded in 1983 by Dilip Shanghvi. The company began operations with a small portfolio of psychiatry medicines and later expanded into branded generics, speciality medicines, active pharmaceutical ingredients and global pharmaceutical markets. Sun Pharma is headquartered in Mumbai, Maharashtra. The company is listed on the National Stock Exchange under the ticker SUNPHARMA and on the Bombay Stock Exchange under the code 524715.

    Sun Pharma operates in the pharmaceutical sector and manufactures, develops and markets medicines across chronic and acute therapy areas. Its business includes generic formulations, branded generics, speciality products, APIs and over-the-counter products. The company has a presence in more than 100 countries and is supported by a global manufacturing network. 

    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Sun Pharma Advanced Research Company Ltd?

    Answer Field

    Sun Pharma Advanced Research Company Ltd share price is for NSE ₹ 213.21 & for BSE ₹ 211.00 as on Aug 07 2026 03:30 PM.

    What is the Market Cap of Sun Pharma Advanced Research Company Ltd Share?

    Answer Field

    The market cap of Sun Pharma Advanced Research Company Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Aug 07 2026 03:30 PM.

    What is the 52 Week High and Low of Sun Pharma Advanced Research Company Ltd?

    Answer Field

    The 52 Week High and Low of Sun Pharma Advanced Research Company Ltd for NSE is ₹ 289.00 and ₹ 108.00 and for BSE is ₹ 289.00 and ₹ 108.20.

    What is 1 year return for Sun Pharma Advanced Research Company Ltd?

    Answer Field

    The 1 year returns on the stock has been 54.43%.

    What is the P/E Ratio of Sun Pharma Advanced Research Company Ltd Share?

    Answer Field

    As on Aug 07 2026 03:30 PM the price-to-earnings (PE) ratio for Sun Pharma Advanced Research Company Ltd share is 4.54.

    What is the PB ratio of Sun Pharma Advanced Research Company Ltd Share?

    Answer Field

    As on Aug 07 2026 03:30 PM, the price-to-book (PB) ratio for Sun Pharma Advanced Research Company Ltd share is 41.09.

    How to Buy Sun Pharma Advanced Research Company Ltd Share?

    Answer Field

    You can trade in Sun Pharma Advanced Research Company Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Sun Pharma Advanced Research Company Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Sun Pharma Advanced Research Company Ltd shares on the Bajaj Broking app, follow these steps:

    1. Login to the Bajaj Broking App

    2. Click on the Search Icon

    3. Search “Sun Pharma Advanced Research Company Ltd”

    4. Click on the BUY icon

    5. Place a buy order specifying the desired quantity of shares.

    6. Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |